Caroline Rynn
Impact in
- Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria
-
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
Papers in
-
- Ubiquitin and proteasome pathways 4
- Protein Degradation and Inhibitors 2
- Protein purification and stability 1
- Histone Deacetylase Inhibitors Research 1
- Cancer therapeutics and mechanisms 1
- Oncology 6
- Cancer-related Molecular Pathways 4
- Co-authors
- Isabelle Walter (1 shared paper)Carina Cantrill (1 shared paper)Prasoon Chaturvedi (1 shared paper)Matthias Wittwer (2 shared papers)Pascal Furet (4 shared papers)Stéphane Ferretti (4 shared papers)Stefan Stutz (4 shared papers)Philipp Holzer (4 shared papers)
- Journals
- Journal of Medicinal Chemistry (2 papers)Drug Discovery Today (2 papers)Cancer Research (2 papers)Clinical Microbiology and Infection (1 paper)BMC Pharmacology and Toxicology (1 paper)
- Partner nations
- SwitzerlandUnited StatesUnited Kingdom
In The Last Decade
Caroline Rynn
11 papers receiving 397 citations
Peers
Comparison fields: 5 of 58
- Molecular Medicine 34
- Oncology 171
- Hematology 46
- Molecular Biology 272
- Applied Microbiology and Biotechnology 5
Countries citing papers authored by Caroline Rynn
This map shows the geographic impact of Caroline Rynn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Rynn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Rynn more than expected).
Fields of papers citing papers by Caroline Rynn
This network shows the impact of papers produced by Caroline Rynn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Rynn. The network helps show where Caroline Rynn may publish in the future.
Co-authors
The 25 scholars most cited alongside Caroline Rynn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 155 | |
| 2 | 2020 | 117 | |
| 3 | 1999 | 41 | |
| 4 | 2023 | 34 | |
| 5 | 2018 | 18 | |
| 6 | 2022 | 10 | |
| 7 | 2025 | 9 | |
| 8 | 2017 | 8 | |
| 9 | 2016 | 7 | |
| 10 | 2023 | 3 | |
| 11 | 2014 | 2 | |
| 12 | 2022 | 0 | |
| 13 | 2022 | 0 |
About Caroline Rynn
Caroline Rynn is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cell Biology and Pharmacology, having authored 13 papers that have together received 404 indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (4 papers), Cancer-related Molecular Pathways (4 papers), Protein Degradation and Inhibitors (2 papers), Microtubule and mitosis dynamics (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Protein purification and stability (1 paper), Histone Deacetylase Inhibitors Research (1 paper) and Cancer therapeutics and mechanisms (1 paper). The work is most often cited by research in Molecular Medicine (34 citations), Oncology (171 citations), Hematology (46 citations), Molecular Biology (272 citations) and Applied Microbiology and Biotechnology (5 citations). Caroline Rynn has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Isabelle Walter, Carina Cantrill, Prasoon Chaturvedi, Matthias Wittwer, Pascal Furet, Stéphane Ferretti, Stefan Stutz, Philipp Holzer, Stephan Ruetz and Therese‐Marie Stachyra. Their work appears in journals such as Journal of Medicinal Chemistry, Drug Discovery Today, Cancer Research, Clinical Microbiology and Infection and BMC Pharmacology and Toxicology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.